(Q51120622)

30 March 2018

title

Prostate-specific antigen screening among young men in the United States. (English)

1 reference

30 March 2018

author name string

Charles D Scales

1

1 reference

30 March 2018

Jodi Antonelli

2

1 reference

30 March 2018

Lesley H Curtis

3

1 reference

30 March 2018

Kevin A Schulman

4

1 reference

30 March 2018

Judd W Moul

5

1 reference

30 March 2018

language of work or name

English

0 references

publication date

1 September 2008

1 reference

30 March 2018

published in

Cancer

1 reference

30 March 2018

volume

113

1 reference

30 March 2018

issue

6

1 reference

30 March 2018

page(s)

1315-1323

1 reference

30 March 2018

Viewpoint: expanding prostate cancer screening

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

Viewpoint: limiting prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

Prostate-specific antigen screening in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

Prostate cancer screening between low-income African-American and Caucasian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

American Cancer Society guidelines for the early detection of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Cancer of the Prostate in Men Less than 50 Years Old: An Analysis of 51 Cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

A private practice experience with adenocarcinoma of the prostate in men less than 50 years old.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

CLINICAL ADENOCARCINOMA OF THE PROSTATE IN PATIENTS UNDER 50 YEARS OF AGE

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Prostate specific antigen testing in men older than 75 years in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

PSA screening among elderly men with limited life expectancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Racial differences in screening for prostate cancer in the elderly.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Knowledge, attitudes, and screening practices among older men regarding prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Use and awareness of prostate specific antigen tests and race/ethnicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Cancer screening among Latino subgroups in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Relationship of demographic and clinical factors to free and total prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Obesity and prostate cancer screening in the USA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Relationship between body mass index and prostate cancer screening in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

The value of current diagnostic tests in prostate cancer screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Prostate cancer: the price of early detection.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23667

7 January 2021

Identifiers

DOI

10.1002/CNCR.23667

1 reference

30 March 2018

1 reference

30 March 2018